Soleus Capital

Total investments

59

Average round size

99M

Portfolio companies

46

Rounds per year

9.83

Lead investments

4

Follow on index

0.20

Exits

18

Stages of investment
Private EquityEarly Stage Venture
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Investments analytics

Analytics

Total investments
59
Lead investments
4
Exits
18
Rounds per year
9.83
Follow on index
0.20
Investments by industry
  • Biotechnology (45)
  • Health Care (39)
  • Medical Device (18)
  • Medical (14)
  • Therapeutics (13)
  • Show 19 more
Investments by region
  • United States (46)
  • United Kingdom (4)
  • Canada (3)
  • Denmark (2)
  • Israel (1)
  • Show 2 more
Peak activity year
2021
Number of Unicorns
1
Number of Decacorns
1
Number of Minotaurs
2

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
10
Avg. valuation at time of investment
33M
Group Appearance index
1.00
Avg. company exit year
10
Avg. multiplicator
1.05
Strategy success index
1.00

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
AltruBio 21 May 2024 Biotechnology, Health Care, Medical Early Stage Venture 225M United States, California
ArcherDX 17 Dec 2019 Biotechnology, Genetics, Life Science, Biopharma Late Stage Venture 55M United States, Boulder, Colorado

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.